Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2015
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationSyed M Kazmi, Maliha Nusrat, Hilal Gunaydin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
American Journal of Hematology|December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapyElias Jabbour, Naval Daver, Richard Champlin, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer|September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaIdrees Mian, Denái R Milton, Nina Shah, et al.
American Journal of Hematology|May 13, 2026
Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell TransplantGeorge L Chen, Roland Bassett, Rohtesh S Mehta, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
American Journal of Hematology|January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyElias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2015
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationSyed M Kazmi, Maliha Nusrat, Hilal Gunaydin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Current Research in Translational Medicine|January 27, 2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplantArmin Ghobadi, Denái R Milton, Lohith Gowda, et al.
American Journal of Hematology|December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapyElias Jabbour, Naval Daver, Richard Champlin, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer|September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaIdrees Mian, Denái R Milton, Nina Shah, et al.
American Journal of Hematology|May 13, 2026
Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell TransplantGeorge L Chen, Roland Bassett, Rohtesh S Mehta, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
American Journal of Hematology|January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyElias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Pageof 15